INO: INO-3107 nears FDA decision, backed by strong trial data and commercial launch preparations
A proprietary DNA medicines platform is advancing toward potential approval with INO-3107 for RRP, showing strong efficacy and safety in trials. Commercial readiness is high, with a focused market strategy and robust pipeline, while financials support operations through early 2027.Based on Inovio P…